Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Musculoskeletal and pulmonary outcomes of sarcoidosis after initial presentation of osseous involvement.

Miller ER, Fanta CH, McSparron JI, Pan B, Coblyn JS, Sparks JA.

Sarcoidosis Vasc Diffuse Lung Dis. 2019;36(1):60-63. Epub 2019 Mar 11.

2.

Mixed-effects association of single cells identifies an expanded effector CD4+ T cell subset in rheumatoid arthritis.

Fonseka CY, Rao DA, Teslovich NC, Korsunsky I, Hannes SK, Slowikowski K, Gurish MF, Donlin LT, Lederer JA, Weinblatt ME, Massarotti EM, Coblyn JS, Helfgott SM, Todd DJ, Bykerk VP, Karlson EW, Ermann J, Lee YC, Brenner MB, Raychaudhuri S.

Sci Transl Med. 2018 Oct 17;10(463). pii: eaaq0305. doi: 10.1126/scitranslmed.aaq0305.

3.

Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis.

Rao DA, Gurish MF, Marshall JL, Slowikowski K, Fonseka CY, Liu Y, Donlin LT, Henderson LA, Wei K, Mizoguchi F, Teslovich NC, Weinblatt ME, Massarotti EM, Coblyn JS, Helfgott SM, Lee YC, Todd DJ, Bykerk VP, Goodman SM, Pernis AB, Ivashkiv LB, Karlson EW, Nigrovic PA, Filer A, Buckley CD, Lederer JA, Raychaudhuri S, Brenner MB.

Nature. 2017 Feb 1;542(7639):110-114. doi: 10.1038/nature20810.

4.

A Quality Improvement Approach to Rheumatoid Arthritis Management With Biologic Disease-Modifying Antirheumatic Drugs: Assessing Variability in a Treatment Pathway.

Dave AJ, Tory HO, Awosogba JA, Coblyn JS, Bermas B, Solomon DH, Desai SP.

J Clin Rheumatol. 2017 Jan;23(1):66-69. doi: 10.1097/RHU.0000000000000474. No abstract available.

PMID:
28002163
5.

The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis.

Liao KP, Playford MP, Frits M, Coblyn JS, Iannaccone C, Weinblatt ME, Shadick NS, Mehta NN.

J Am Heart Assoc. 2015 Jan 30;4(2). pii: e001588. doi: 10.1161/JAHA.114.001588.

6.

Osseous sarcoidosis: clinical characteristics, treatment, and outcomes--experience from a large, academic hospital.

Sparks JA, McSparron JI, Shah N, Aliabadi P, Paulson V, Fanta CH, Coblyn JS.

Semin Arthritis Rheum. 2014 Dec;44(3):371-9. doi: 10.1016/j.semarthrit.2014.07.003. Epub 2014 Jul 15.

PMID:
25129260
7.

The influence of polygenic risk scores on heritability of anti-CCP level in RA.

Cui J, Taylor KE, Lee YC, Källberg H, Weinblatt ME, Coblyn JS, Klareskog L, Criswell LA, Gregersen PK, Shadick NA, Plenge RM, Karlson EW.

Genes Immun. 2014 Mar;15(2):107-14. doi: 10.1038/gene.2013.68. Epub 2014 Jan 2.

8.

Hypogalactosylation of serum N-glycans fails to predict clinical response to methotrexate and TNF inhibition in rheumatoid arthritis.

Ercan A, Cui J, Hazen MM, Batliwalla F, Royle L, Rudd PM, Coblyn JS, Shadick N, Weinblatt ME, Gregersen P, Lee DM, Nigrovic PA.

Arthritis Res Ther. 2012 Mar 5;14(2):R43. doi: 10.1186/ar3756.

9.

Clinical predictors of erosion-free status in rheumatoid arthritis: a prospective cohort study.

Liao KP, Weinblatt ME, Cui J, Iannaccone C, Chibnik LB, Lu B, Coblyn JS, Shadick NA, Solomon DH.

Rheumatology (Oxford). 2011 Aug;50(8):1473-9. doi: 10.1093/rheumatology/ker129. Epub 2011 Mar 29.

10.

A novel anti-inflammatory role for secretory phospholipase A2 in immune complex-mediated arthritis.

Boilard E, Lai Y, Larabee K, Balestrieri B, Ghomashchi F, Fujioka D, Gobezie R, Coblyn JS, Weinblatt ME, Massarotti EM, Thornhill TS, Divangahi M, Remold H, Lambeau G, Gelb MH, Arm JP, Lee DM.

EMBO Mol Med. 2010 May;2(5):172-87. doi: 10.1002/emmm.201000072.

11.

Platelets amplify inflammation in arthritis via collagen-dependent microparticle production.

Boilard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, Weinblatt ME, Massarotti EM, Remold-O'Donnell E, Farndale RW, Ware J, Lee DM.

Science. 2010 Jan 29;327(5965):580-3. doi: 10.1126/science.1181928.

12.
13.

Progressive arm and leg stiffness in a patient with chronic renal impairment.

Shin K, Granter SR, Coblyn JS, Gupta S.

Nat Clin Pract Rheumatol. 2008 Oct;4(10):557-62. doi: 10.1038/ncprheum0883. Epub 2008 Aug 19.

PMID:
18711420
14.

Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis.

Agarwal SK, Glass RJ, Shadick NA, Coblyn JS, Anderson RJ, Maher NE, Weinblatt ME, Solomon DH.

J Rheumatol. 2008 Sep;35(9):1737-44. Epub 2008 Jul 15.

15.

Measuring quality of care for rheumatic diseases using an electronic medical record.

Agnew-Blais JC, Coblyn JS, Katz JN, Anderson RJ, Mehta J, Solomon DH.

Ann Rheum Dis. 2009 May;68(5):680-4. doi: 10.1136/ard.2008.089318. Epub 2008 May 29.

16.

Infections, drugs, and rheumatoid arthritis. What have we learned?

Coblyn JS.

J Rheumatol. 2008 Mar;35(3):375-6. No abstract available.

PMID:
18322972
17.

Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate.

Parker A, Izmailova ES, Narang J, Badola S, Le T, Roubenoff R, Ginsburg GS, Maier A, Coblyn JS, Shadick NA, Weinblatt ME.

J Rheumatol. 2007 Sep;34(9):1817-22. Epub 2007 Aug 1.

PMID:
17696278
18.

Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study.

Karlson EW, Chibnik LB, Cui J, Plenge RM, Glass RJ, Maher NE, Parker A, Roubenoff R, Izmailova E, Coblyn JS, Weinblatt ME, Shadick NA.

Ann Rheum Dis. 2008 Mar;67(3):358-63. Epub 2007 Jul 31.

19.

Osteoporosis management in patients with rheumatoid arthritis: Evidence for improvement.

Solomon DH, Katz JN, Cabral D, Patrick AR, Bukowski JF, Coblyn JS.

Arthritis Rheum. 2006 Dec 15;55(6):873-7.

20.

Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study.

Johnsen AK, Schiff MH, Mease PJ, Moreland LW, Maier AL, Coblyn JS, Helfgott SM, Leff JA, Weinblatt ME.

J Rheumatol. 2006 Apr;33(4):659-64. Epub 2006 Feb 15.

PMID:
16482646
21.

Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center.

Agarwal SK, Maier AL, Chibnik LB, Coblyn JS, Fossel A, Lee R, Fanikos J, Fiumara K, Lowry C, Weinblatt ME.

Arthritis Rheum. 2005 Dec 15;53(6):872-8.

22.

Characterization of relapses in adult idiopathic inflammatory myopathies.

Agarwal SK, Monach PA, Docken WP, Coblyn JS.

Clin Rheumatol. 2006 Jul;25(4):476-81. Epub 2005 Nov 3.

PMID:
16267604
23.

Statin therapy in rheumatoid arthritis.

Costenbader KH, Coblyn JS.

South Med J. 2005 May;98(5):534-40; quiz 541, 572. Review.

PMID:
15954510
24.
25.

Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders.

Matsumoto I, Lee DM, Goldbach-Mansky R, Sumida T, Hitchon CA, Schur PH, Anderson RJ, Coblyn JS, Weinblatt ME, Brenner M, Duclos B, Pasquali JL, El-Gabalawy H, Mathis D, Benoist C.

Arthritis Rheum. 2003 Apr;48(4):944-54.

27.

Experience with etanercept in an academic medical center: are infection rates increased?

Phillips K, Husni ME, Karlson EW, Coblyn JS.

Arthritis Rheum. 2002 Feb;47(1):17-21.

PMID:
11932873
28.

Leflunomide-associated weight loss in rheumatoid arthritis.

Coblyn JS, Shadick N, Helfgott S.

Arthritis Rheum. 2001 May;44(5):1048-51.

29.

Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation: a consecutive series.

Bienfang D, Coblyn JS, Liang MH, Corzillius M.

J Rheumatol. 2000 Nov;27(11):2703-6.

PMID:
11093457
30.

Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis.

Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M, Byrne VM, Kaymakcian MV, Strand V.

Arthritis Rheum. 1999 Jul;42(7):1322-8.

31.

Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy.

Weinblatt ME, Maier AL, Fraser PA, Coblyn JS.

J Rheumatol. 1998 Feb;25(2):238-42.

PMID:
9489813
32.

CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study.

Weinblatt ME, Maddison PJ, Bulpitt KJ, Hazleman BL, Urowitz MB, Sturrock RD, Coblyn JS, Maier AL, Spreen WR, Manna VK, et al.

Arthritis Rheum. 1995 Nov;38(11):1589-94.

PMID:
7488279
33.

Lack of a renal-protective effect of misoprostol in rheumatoid arthritis patients receiving cyclosporin A. Results of a randomized, placebo-controlled trial.

Weinblatt ME, Germain BF, Kremer JM, Wall BA, Weisman MH, Maier AL, Coblyn JS.

Arthritis Rheum. 1994 Sep;37(9):1321-5.

PMID:
7945495
34.

Bronchiectasis. A late feature of severe rheumatoid arthritis.

Shadick NA, Fanta CH, Weinblatt ME, O'Donnell W, Coblyn JS.

Medicine (Baltimore). 1994 May;73(3):161-70.

PMID:
8190039
36.

Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis.

Weinblatt ME, Kremer JM, Coblyn JS, Helfgott S, Maier AL, Petrillo G, Henson B, Rubin P, Sperling R.

J Rheumatol. 1992 Oct;19(10):1537-41.

PMID:
1334515
37.

Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate.

Sperling RI, Benincaso AI, Anderson RJ, Coblyn JS, Austen KF, Weinblatt ME.

Arthritis Rheum. 1992 Apr;35(4):376-84.

PMID:
1314609
38.

Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update.

Weinblatt ME, Weissman BN, Holdsworth DE, Fraser PA, Maier AL, Falchuk KR, Coblyn JS.

Arthritis Rheum. 1992 Feb;35(2):129-37.

PMID:
1734901
39.

Inhibition of leukotriene B4 synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate.

Sperling RI, Coblyn JS, Larkin JK, Benincaso AI, Austen KF, Weinblatt ME.

Arthritis Rheum. 1990 Aug;33(8):1149-55.

PMID:
2167685
40.

Rheumatoid aortitis: a rarely recognized but clinically significant entity.

Gravallese EM, Corson JM, Coblyn JS, Pinkus GS, Weinblatt ME.

Medicine (Baltimore). 1989 Mar;68(2):95-106.

PMID:
2921941
41.

The effect of cyclosporine on urinary kallikrein excretion in patients with rheumatoid arthritis.

Spragg J, Coblyn JS, Fraser PA, Austen KF, Weinblatt ME.

Adv Exp Med Biol. 1989;247A:389-92.

PMID:
2603807
42.

Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis.

Weinblatt ME, Trentham DE, Fraser PA, Holdsworth DE, Falchuk KR, Weissman BN, Coblyn JS.

Arthritis Rheum. 1988 Feb;31(2):167-75.

PMID:
3279962
43.

Immunogenetic and racial determinants of gold toxicity in rheumatoid arthritis.

Fraser PA, Stern SH, Coblyn JS, Weinblatt ME, Holdsworth DE, Green P, Shriner S, Mindnich D, Larson M.

J Natl Med Assoc. 1988 Feb;80(2):162-5.

44.

Effects of dietary supplementation with marine fish oil on leukocyte lipid mediator generation and function in rheumatoid arthritis.

Sperling RI, Weinblatt M, Robin JL, Ravalese J 3rd, Hoover RL, House F, Coblyn JS, Fraser PA, Spur BW, Robinson DR, et al.

Arthritis Rheum. 1987 Sep;30(9):988-97.

PMID:
3663263
45.

Diminution of the T8 subset by amiprilose hydrochloride in refractory RA.

Weinblatt ME, Fraser PA, Anderson R, Coblyn JS, Trentham DE.

J Rheumatol. 1987 Aug;14(4):859-60. No abstract available.

PMID:
3499514
46.

Cyclosporin A treatment of refractory rheumatoid arthritis.

Weinblatt ME, Coblyn JS, Fraser PA, Anderson RJ, Spragg J, Trentham DE, Austen KF.

Arthritis Rheum. 1987 Jan;30(1):11-7.

PMID:
3814192
47.
48.

Cerebral vasculopathy: an analysis of sixteen cases.

Bryant GL, Weinblatt ME, Rumbaugh C, Coblyn JS.

Semin Arthritis Rheum. 1986 May;15(4):297-302. No abstract available.

PMID:
3715476
49.

Efficacy of low-dose methotrexate in rheumatoid arthritis.

Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, Trentham DE.

N Engl J Med. 1985 Mar 28;312(13):818-22.

PMID:
3883172
50.

Extended haplotypes of chromosome 6 in adult rheumatoid arthritis.

Raum D, Awdeh Z, Glass D, Kammer G, Khan MA, Coblyn JS, Weinblatt M, Holdsworth D, Strong L, Rossen RD, et al.

Arthritis Rheum. 1984 May;27(5):516-21.

PMID:
6586181

Supplemental Content

Loading ...
Support Center